Health Catalyst (NASDAQ:HCAT – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.
Analyst Ratings
This is a breakdown of recent recommendations for Health Catalyst and SOPHiA GENETICS, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Health Catalyst | 1 | 8 | 4 | 0 | 2.23 |
| SOPHiA GENETICS | 1 | 0 | 2 | 0 | 2.33 |
Health Catalyst currently has a consensus target price of $2.77, indicating a potential upside of 69.07%. SOPHiA GENETICS has a consensus target price of $7.50, indicating a potential upside of 44.23%. Given Health Catalyst’s higher probable upside, equities analysts clearly believe Health Catalyst is more favorable than SOPHiA GENETICS.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Health Catalyst | -87.69% | -3.52% | -1.77% |
| SOPHiA GENETICS | -44.48% | -62.74% | -21.85% |
Risk & Volatility
Health Catalyst has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
Valuation & Earnings
This table compares Health Catalyst and SOPHiA GENETICS”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Health Catalyst | $311.14 million | 0.39 | -$177.97 million | ($3.72) | -0.44 |
| SOPHiA GENETICS | $81.18 million | 4.39 | -$79.00 million | ($0.52) | -10.00 |
SOPHiA GENETICS has lower revenue, but higher earnings than Health Catalyst. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Health Catalyst beats SOPHiA GENETICS on 9 of the 14 factors compared between the two stocks.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
